Home » German Bundestag – Dealing with therapy allergens

German Bundestag – Dealing with therapy allergens

by admin
German Bundestag – Dealing with therapy allergens

Berlin: (hib/PK) The federal government defends the handling of therapy allergens against criticism from the Union faction. The demand that non-approved therapy allergens or those in the process of being re-approved should be withdrawn from the market before the end of the transition period provided for in the Therapy Allergen Ordinance (TAV) due to a lack of effectiveness is not justified, the answer says (20/7056) of the Federal Government on a small inquiry (20/6620) of the CDU/CSU parliamentary group.

If there are justified doubts about the approval of individual TAV preparations or if study data are not submitted by the set deadline, the Paul Ehrlich Institute (PEI) has the option of refusing to extend the deadline or refuse to release further batches. The PEI makes use of these options in such cases. Irrespective of this, as with other medicinal products, unauthorized individual formulations could be prescribed and used.

See also  Outstanding 12-month results from SELUTION SFA study presented at JET

You may also like

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy